HSA Pre-Submission Meetings: Why They Matter for New Drug and Biologic Approvals in Singapore

---

Key Takeaways

• Health Sciences Authority (HSA) pre-submission meeting ensures that companies clarify data expectations and regulatory requirements. 
• Early clarification with HSA can minimise costly delays due to non acceptance of bridging data, inadequate demonstration of efficacy studies to claimed indications
• Preparing clear briefing documents, agendas, and supporting data ensures productive discussions.
• The Reg Consultants provides pharma regulatory services to help clients navigate HSA guidelines with confidence.

Why Pre-Submission Meetings Are a Strategic Advantage

For companies planning a new drug application or biologic submission in Singapore, the pre-submission meeting with Health Sciences Authority (HSA) can be a critical step especially if your product is a novel therapeutic product and developed in the absence of, or deviates from local or international regulatory guidance. This meeting allows applicants to align on data expectations, clarify regulatory requirements, and proactively address potential gaps—significantly reducing the risk of delays or additional queries.

At The Reg Consultants (TRC), we guide clients through every stage of the process, from preparing the right documents to rehearsing answers for HSA’s most likely questions. Here’s what you can expect from the process and how to prepare effectively.

What is a HSA Pre-Submission Meeting, and When is it Needed?

A HSA pre-submission consultation is recommended for new chemical entities (NCEs), biologics, biosimilars, and other complex therapeutic products which has never been approved anywhere else in the world or has new approaches to the development of the drug which might imapact on the safety and quality which they need consultation on . It is typically scheduled before submitting a new drug application or major variation.

During this session, you can present clinical data, manufacturing details, and proposed indications directly to HSA reviewers. Addressing these questions early will help you and your company avoid major data misalignments or gaps that often result in prolonged review cycles. In fact, having clear discussions with HSA upfront can save three to six months on overall submission timelines, giving your product a faster path to approval.

Required Documents for the Meeting

To maximise the value of the pre-submission meeting, it is important to provide clear, well-organised documents. These include:

• Proposed agenda for the meeting;
• Summary information which may include Chemistry, Manufacturing and Controls (CMC)/ non-clinical/ clinical information of the product and proposed application;
• Specific scientific issues that require advice

Preparing these materials ahead of time and aligning with guidelines ensures that the HSA has all the necessary information, allowing them to provide meaningful feedback.

Common HSA Questions for NCE and Biologic Submissions

During pre-submission meetings, HSA reviewers often raise questions that test both scientific and regulatory readiness. Here are some of the areas they may focus on:

• The design of clinical trials and whether the selected endpoints are appropriate.
• Comparability data and evidence supporting biosimilars.
• The justification for proposed indications, dosage, and target patient population.
• Manufacturing processes, quality controls, and overall assurance of product consistency.
• Plans for post-market surveillance and risk management.

Since these questions often require detailed and well-supported answers, having a trusted regulatory affairs consultant by your side can make a critical difference. TRC offers tailored mock Q&A sessions to help technical and regulatory teams practise their responses. This proactive approach ensures your team is well-prepared to engage with reviewers, demonstrate compliance, and address even the most challenging queries.

How TRC Prepares Clients for Successful Meetings

At The Reg Consultants, our role goes beyond document preparation, providing comprehensive regulatory support and guidance tailored to each client’s needs. This includes:

• Gap assessments to evaluate dossier readiness before engaging HSA.
• Drafting briefing documents that anticipate regulatory concerns.
• Running mock Q&A rehearsals to strengthen the preparedness of your technical team.
• Advising on meeting strategies, including how to present risk areas and mitigation measures.
• Documenting agreements made during the meeting to avoid disputes later in the approval process.

Through this structured approach, we empower clients to approach HSA pre-submission meetings with confidence, all while ensuring that outcomes are clear and actionable. 

Why HSA Guidance Matters for NCE and Biologics

A HSA pre-submission meeting should be viewed not as a procedural step but as a strategic opportunity. Key benefits include:

• Reduced risk of delays, additional data requests, or outright rejection.
• Early alignment with HSA guidelines, which reduces uncertainty over evidence thresholds.
• Greater clarity on regulatory expectations.

For companies submitting a biologics licence application or new drug dossier, pre-submission meetings are invaluable in accelerating time-to-market and building trust with regulators.

Preparing for Approval with Guidance You Can Trust

A HSA pre-submission meeting is more than a formality. Rather, it’s a valuable opportunity to strengthen your regulatory submissions, anticipate authority concerns, and accelerate approval timelines. With TRC’s proven expertise in HSA registration and regulatory support in Singapore, we can help your team approach these meetings fully prepared, confident, and aligned with HSA guidelines. 

Partner with us today to set your submission on the right path from the start.

• Share This Article:

---